Recursion Pharmaceuticals, Inc.
RXRX
$5.68
-$0.27-4.54%
NASDAQ
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 29.32% | 32.00% | 37.64% | -0.70% | -0.88% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 29.32% | 32.00% | 37.64% | -0.70% | -0.88% |
| Cost of Revenue | 42.51% | 26.72% | 26.47% | 37.28% | 36.15% |
| Gross Profit | -44.88% | -25.74% | -23.97% | -47.56% | -45.95% |
| SG&A Expenses | 67.19% | 60.86% | 30.25% | 34.69% | 41.76% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 49.53% | 36.31% | 27.53% | 36.55% | 37.70% |
| Operating Income | -52.00% | -36.86% | -26.01% | -43.28% | -44.58% |
| Income Before Tax | -60.27% | -39.94% | -30.89% | -46.27% | -44.26% |
| Income Tax Expenses | 89.53% | 72.23% | -- | -- | -- |
| Earnings from Continuing Operations | -62.31% | -41.33% | -29.12% | -44.21% | -42.31% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -62.31% | -41.33% | -29.12% | -44.21% | -42.31% |
| EBIT | -52.00% | -36.86% | -26.01% | -43.28% | -44.58% |
| EBITDA | -50.34% | -35.91% | -24.03% | -39.72% | -40.70% |
| EPS Basic | -9.78% | -5.65% | -5.48% | -18.89% | -17.32% |
| Normalized Basic EPS | -8.13% | -4.81% | -6.76% | -20.19% | -18.49% |
| EPS Diluted | -10.00% | -5.88% | -5.53% | -18.89% | -17.32% |
| Normalized Diluted EPS | -8.13% | -4.81% | -6.76% | -20.19% | -18.49% |
| Average Basic Shares Outstanding | 44.42% | 32.07% | 24.08% | 21.75% | 21.02% |
| Average Diluted Shares Outstanding | 44.42% | 32.07% | 24.08% | 21.75% | 21.02% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |